Table 1.

Safety summary.

	Double-blind Period,^* ABA Group (1 yr; n = 433)	Cumulative Period,^† All ABA-treated Patients (5 yrs; n = 594)
	Incidence rate (events/100 patient-yrs)
Adverse events	303.4	242.32
Serious adverse events	17.7	13.87
Infections	90.5	67.14
Serious infections	4.2	2.84
Malignancies	1.7	1.45
Autoimmune events	2.5	0.99

↵* Data are for patients randomized to abatacept during the double-blind period.
↵† Data are for all patients who had received at least 1 dose of abatacept in the double-blind or longterm extension period, regardless of treatment group during the double-blind period. ABA: abatacept.